Alan Sebulsky bought $474k of PBLS
director at Parabilis Medicines, Inc.. 17,500 shares at an average of $27.06, traded Jun 12, 2026, filed Jun 16, 2026.
Score components
- +15RoleDirector
- +17Trade size$474k at market
- +10Relative to holdingsHoldings up 140%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-273013, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | POpen-market purchase Common Stockindirect: By Apothecary Capital LLC | +8,435 | $27.67 | $233k | 20,935 | Jun 16, 2026 |
| Jun 15, 2026 | POpen-market purchase Common Stockindirect: By Apothecary Capital LLC | +5,000 | $26.00 | $130k | 25,935 | Jun 16, 2026 |
| Jun 15, 2026 | POpen-market purchase Common Stockindirect: By Apothecary Capital LLC | +4,065 | $27.10 | $110k | 30,000 | Jun 16, 2026 |
Related signals
Other insiders at Parabilis Medicines, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | PBLSbuy Parabilis Medicines, Inc. | Ra Capital Management, L.p. director, owner | $6.9M 244,593 shares | +1% | |
| 57Moderate | Parabilis Medicines, Inc. | Guy Levy owner | $10M 500,000 shares | +77% | |
| 60Notable | Parabilis Medicines, Inc. | Ra Capital Management, L.p. director, owner | $424M 21,188,750 shares | +323% | |
| 51Moderate | Parabilis Medicines, Inc. | Alan Sebulsky director | $250k 12,500 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.